The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

EHA 2021 | Horizon scan of T-cell lymphoma therapy

Name: Horizon scan of T-cell lymphoma therapy
Uploaded: 2021-06-14T00:00:00Z
Duration: 48 s
Description: Deepa Jagadeesh, MD, PhD, Case Comprehensive Cancer Center, Cleveland, OH, comments on the future of upfront treatments for T-cell lymphomas, in particular highlighting a study of Pi3 kinase in the upfront setting. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Deepa Jagadeesh • 14 Jun 2021

EHA 2021

Lymphoma Peripheral T-Cell Lymphoma Rare Diseases T-Cell Lymphoma Antibodies Brentuximab vedotin

ECHELON-2

Deepa Jagadeesh, MD, PhD, Case Comprehensive Cancer Center, Cleveland, OH, comments on the future of upfront treatments for T-cell lymphomas, in particular highlighting a study of Pi3 kinase in the upfront setting. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Deepa Jagadeesh, MD, PhD, has received research funding from ADC Therapeutics, AstraZeneca, Debiopharm Group, MEI Pharma, Regeneron, Rhizen Pharma, Seagen, Trillium Therapeutics and LOXO Pharma.